A short review on antibody therapy for COVID-19

The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75,900 deaths. To date, the anti-malaria drug hydroxychl...

Descripción completa

Detalles Bibliográficos
Autores principales: Venkat Kumar, G., Jeyanthi, V., Ramakrishnan, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Mini-Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167584/
https://www.ncbi.nlm.nih.gov/pubmed/32313660
http://dx.doi.org/10.1016/j.nmni.2020.100682
_version_ 1783523592875540480
author Venkat Kumar, G.
Jeyanthi, V.
Ramakrishnan, S.
author_facet Venkat Kumar, G.
Jeyanthi, V.
Ramakrishnan, S.
author_sort Venkat Kumar, G.
collection PubMed
description The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75,900 deaths. To date, the anti-malaria drug hydroxychloroquine found to be a treatment option for SARS-CoV-2. In addition to supportive treatment, such as oxygen supply in moderate cases and extracorporeal membrane oxygenation in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed the antibody therapy might be an immediate strategy for emergency prophylaxis and SARS-CoV-2 therapy.
format Online
Article
Text
id pubmed-7167584
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-71675842020-05-04 A short review on antibody therapy for COVID-19 Venkat Kumar, G. Jeyanthi, V. Ramakrishnan, S. New Microbes New Infect Mini-Review The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75,900 deaths. To date, the anti-malaria drug hydroxychloroquine found to be a treatment option for SARS-CoV-2. In addition to supportive treatment, such as oxygen supply in moderate cases and extracorporeal membrane oxygenation in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed the antibody therapy might be an immediate strategy for emergency prophylaxis and SARS-CoV-2 therapy. Elsevier 2020-04-20 /pmc/articles/PMC7167584/ /pubmed/32313660 http://dx.doi.org/10.1016/j.nmni.2020.100682 Text en © 2020 Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Mini-Review
Venkat Kumar, G.
Jeyanthi, V.
Ramakrishnan, S.
A short review on antibody therapy for COVID-19
title A short review on antibody therapy for COVID-19
title_full A short review on antibody therapy for COVID-19
title_fullStr A short review on antibody therapy for COVID-19
title_full_unstemmed A short review on antibody therapy for COVID-19
title_short A short review on antibody therapy for COVID-19
title_sort short review on antibody therapy for covid-19
topic Mini-Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167584/
https://www.ncbi.nlm.nih.gov/pubmed/32313660
http://dx.doi.org/10.1016/j.nmni.2020.100682
work_keys_str_mv AT venkatkumarg ashortreviewonantibodytherapyforcovid19
AT jeyanthiv ashortreviewonantibodytherapyforcovid19
AT ramakrishnans ashortreviewonantibodytherapyforcovid19
AT venkatkumarg shortreviewonantibodytherapyforcovid19
AT jeyanthiv shortreviewonantibodytherapyforcovid19
AT ramakrishnans shortreviewonantibodytherapyforcovid19

Ejemplares similares